MCID: RTN024
MIFTS: 73

Retinoblastoma malady

Categories: Genetic diseases, Rare diseases, Eye diseases, Cancer diseases, Neuronal diseases, Endocrine diseases

Aliases & Classifications for Retinoblastoma

About this section
Sources:
49OMIM, 10Disease Ontology, 11diseasecard, 68Wikipedia, 21GeneReviews, 45NIH Rare Diseases, 22GeneTests, 23Genetics Home Reference, 47Novoseek, 12DISEASES, 51Orphanet, 24GTR, 65UMLS, 67UniProtKB/Swiss-Prot, 36MeSH, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 34MedGen, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Retinoblastoma:

Name: Retinoblastoma 49 10 11 68 21 45 22 23 47 12 51 24 65
Rb 10 68 45 23 67
Trilateral Retinoblastoma 10 12 24 65
Glioma, Retinal 68 23
Childhood Cancer Retinoblastoma 67
Malignant Neoplasm of Retina 65
Eye Cancer, Retinoblastoma 45
Retinoblastoma, Trilateral 49
 
Neuroblastoma of Retina 10
Neuroblastoma, Retinal 68
Glioblastoma, Retinal 68
Rb - Retinoblastoma 10
Retinal Neoplasms 65
Retinal Cancer 45
Retinal Tumor 45

Characteristics:

Orphanet epidemiological data:

51
retinoblastoma:
Inheritance: Autosomal dominant,Not applicable; Prevalence: <1/1000000 (Europe),1-9/100000 (Europe),1-9/100000 (Worldwide); Age of onset: Antenatal,Childhood,Infancy,Neonatal; Age of death: any age

HPO:

61


Classifications:



External Ids:

OMIM49 180200
Disease Ontology10 DOID:4647, DOID:768
MeSH36 D012175
NCIt42 C6956, C7541
Orphanet51 790
ICD10 via Orphanet28 C69.2
MESH via Orphanet37 D012175
UMLS via Orphanet66 C0035335
MedGen34 C1867262
UMLS65 C0035335, C2608045

Summaries for Retinoblastoma

About this section
NIH Rare Diseases:45 Retinoblastoma (rb) is a rare type of eye cancer in the retina that typically develops before the age of 5. it usually affects only one eye, but 1/3 of children with rb develop cancer in both eyes. the first sign is typically a visible whiteness in the pupil called "cat's eye reflex" or leukocoria, which is particularly noticeable in photographs taken with a flash. other signs and symptoms include strabismus; persistent eye pain, redness or irritation; and blindness or poor vision in the affected eye(s). retinoblastoma is caused by mutations in the rb1 gene. in about 60% of people with retinoblastoma, mutations are not inherited and occur only in retinal cells. in the other 40% of individuals, mutations are inherited from a parent in an autosomal dominant pattern and can be found in all body cells. retinoblastoma that is caused by an inherited mutation is called hereditary retinoblastoma. hereditary retinoblastoma usually occurs at a younger age than retinoblastoma that is not inherited (15 months vs. 24 months). retinoblastoma that occurs in only one eye is usually not inherited. retinoblastoma that occurs in both eyes is thought to be inherited. last updated: 4/4/2012

MalaCards based summary: Retinoblastoma, also known as rb, is related to intraocular retinoblastoma and unilateral retinoblastoma, and has symptoms including retinoblastoma, ewing's sarcoma and retinoblastoma. An important gene associated with Retinoblastoma is RB1 (Retinoblastoma 1), and among its related pathways are Id Signaling Pathway and Sumoylation by RanBP2 regulates transcriptional repression. The drug cyclophosphamide has been mentioned in the context of this disorder. Affiliated tissues include the pineal or suprasellar region, eye and retina, and related mouse phenotypes are digestive/alimentary and muscle.

Disease Ontology:10 A retinoblastoma that refers to bilateral retinoblastoma associated with an intracranial primitive neuroectodermal tumor located in the pineal or suprasellar region.

UniProtKB/Swiss-Prot:67 Childhood cancer retinoblastoma: Congenital malignant tumor that arises from the nuclear layers of the retina. It occurs in about 1:20'000 live births and represents about 2% of childhood malignancies. It is bilateral in about 30% of cases. Although most RB appear sporadically, about 20% are transmitted as an autosomal dominant trait with incomplete penetrance. The diagnosis is usually made before the age of 2 years when strabismus or a gray to yellow reflex from pupil ('cat eye') is investigated.

Genetics Home Reference:23 Retinoblastoma is a rare type of eye cancer that usually develops in early childhood, typically before the age of 5. This form of cancer develops in the retina, which is the specialized light-sensitive tissue at the back of the eye that detects light and color.

OMIM:49 Retinoblastoma (RB) is an embryonic malignant neoplasm of retinal origin. It almost always presents in early childhood... (180200) more...

Wikipedia:68 Retinoblastoma (Rb) is a rare form of cancer that rapidly develops from the immature cells of a retina,... more...

GeneReviews summary for NBK1452

Related Diseases for Retinoblastoma

About this section

Diseases in the Retinoblastoma family:

Familial Retinoblastoma

Diseases related to Retinoblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 1075)
idRelated DiseaseScoreTop Affiliating Genes
1intraocular retinoblastoma34.7RB1, RBL1
2unilateral retinoblastoma34.4RB1, RBL1
3familial retinoblastoma33.0CDK4, E2F1, E2F3, E2F4, MDM2, PRDM2
4fibrosarcoma30.0CDK4, MDM2, RB1
5pasteurellosis29.8CDK4, E2F3, MDM2, RB1
6marginal zone b-cell lymphoma29.8CDK4, MDM2, RB1
7carbuncle29.1CDK4, E2F1, E2F3, E2F4, MDM2, PRDM2
8bilateral retinoblastoma12.6
9extraocular retinoblastoma12.5
10pediatric intraocular retinoblastoma12.5
11pediatric extraocular retinoblastoma12.5
12retinoblastoma fa - friedreich ataxia12.4
13non-hereditary retinoblastoma12.2
14roberts syndrome11.9
15respiratory bronchiolitis-interstitial lung disease syndrome11.3
16endometriosis10.9
17neuroblastoma10.9
18hiv-110.8
19pulmonary tuberculosis10.8
20huntington disease10.7
21retinal disease10.6
22facial injuries and disorders10.5MDM2, RB1
23angiolipoma10.4CDK4, MDM2
24esophageal lipoma10.4CDK4, MDM2, RB1
25fibrosarcoma of bone10.4CDK4, MDM2
26myxoid chondrosarcoma10.4CDK4, MDM2, RB1
27classic type lipoma10.4CDK4, MDM2, RB1
28median neuropathy10.4CDK4, MDM2, RB1
29small cell osteogenic sarcoma10.4CDK4, MDM2
30breast cancer10.4
31renal cell carcinoma, papillary10.4
32autosomal dominant charcot-marie-tooth disease type 2a210.4CDK4, MDM2, RB1
33epithelioid sarcoma10.4CDK4, MDM2
34hepatitis10.4
35rhabdomyosarcoma 2, alveolar10.4CDK4, MDM2, RB1
36fallopian tube carcinosarcoma10.4CDK4, MDM2, RB1
37endotheliitis10.4
38prostatitis10.3
39leukemia10.3
40lymphoma10.3
41neuronitis10.3
42cell type cancer10.3CDK4, MDM2, RB1
43mixed liposarcoma10.3CDK4, MDM2
44retinitis10.3
45pancreatitis10.3
46chromosome 13q14 deletion syndrome10.3
47norrie disease10.3
48blastoma10.3
49retinal cancer10.3
50adenocarcinoma10.3

Graphical network of the top 20 diseases related to Retinoblastoma:



Diseases related to retinoblastoma

Symptoms for Retinoblastoma

About this section

Symptoms by clinical synopsis from OMIM:

180200

Clinical features from OMIM:

180200

Symptoms:

 51
  • retinoblastoma
  • autosomal dominant inheritance

HPO human phenotypes related to Retinoblastoma:

(show all 10)
id Description Frequency HPO Source Accession
1 retinoblastoma hallmark (90%) HP:0009919
2 ewing's sarcoma HP:0012254
3 retinoblastoma HP:0009919
4 vitreous hemorrhage HP:0007902
5 retinal calcification HP:0007862
6 osteosarcoma HP:0002669
7 lymphoma HP:0002665
8 leukemia HP:0001909
9 leukocoria HP:0000555
10 cleft palate HP:0000175

Drugs & Therapeutics for Retinoblastoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Ibrance15 41 PALBOCICLIB Pfizer February 2015
FDA Label: Ibrance
Disease/s that Drug Treats:ER-positive, HER2-negative breast cancer
Indications and Usage:15 IBRANCE is a kinase inhibitor indicated in combination with letrozole for thetreatment of postmenopausal women with estrogen receptor (ER)-positive,human epidermal growth factor receptor 2 (HER2)-negative advanced breastcancer as initial endocrine-based therapy for their metastatic disease. Thisindication is approved under accelerated approval based on progression-freesurvival (PFS). Continued approval for this indication may be contingentupon verification and description of clinical benefit in a confirmatory trial. (1)
DrugBank Targets:13 1. Cyclin-dependent kinase 4;2. Cyclin-dependent kinase 6
Mechanism of Action:15 
Target: cyclin-dependent kinase (CDK) 4 and 6
Action: inhibitor
FDA: Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. Cyclin D1 and CDK4/6 aredownstream of signaling pathways which lead to cellular proliferation. In vitro, palbociclib reducedcellular proliferation of estrogen receptor (ER)-positive breast cancer cell lines by blocking progressionof the cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell lines with thecombination of palbociclib and antiestrogens leads to decreased retinoblastoma protein (Rb)phosphorylation resulting in reduced E2F expression and signaling and increased growth arrestcompared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lineswith the combination of palbociclib and antiestrogens leads to increased cell senescence, which wassustained for up to 6 days following drug removal. In vivo studies using a patient-derived ER-positivebreast cancer xenograft model demonstrated that the combination of palbociclib and letrozole increasedthe inhibition of Rb phosphorylation, downstream signaling and tumor growth compared to each drugalone.
2
Tasigna15 41 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007
FDA Label: Tasigna
Disease/s that Drug Treats:chronic myelogenous leukemia
Indications and Usage:15 Tasigna is a kinase inhibitor indicated for:The treatment of newly diagnosed adult patients with Philadelphiachromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.The treatment of chronic phase (CP) and accelerated phase (AP) Ph+ CML inadult patients resistant to or intolerant to prior therapy that included imatinib.(1.2)--------------
DrugBank Targets:13 1. Tyrosine-protein kinase ABL1;2. Mast/stem cell growth factor receptor Kit
Mechanism of Action:15 
Target: Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF)
Action: inhibitor of signal transduction
FDA: Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation ofthe kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murineleukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of theassays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 outof 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine BCR-ABL xenograft model.Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: BCR-ABL (20to 60 nM), PDGFR (69 nM), c-KIT (210 nM), CSF-1R (125 to 250 nM), and DDR1 (3.7 nM).
3
Kalydeco15 IVACAFTOR Vertex Pharmaceuticals January of 2012
FDA Label: Kalydeco
Disease/s that Drug Treats:cystic fibrosis with the G551D mutation in the CFTR gene
Indications and Usage:15 KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. KALYDECO is indicated for the treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. (1) Limitations of Use: * Not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene. (1, 14)
DrugBank Targets:13 Cystic fibrosis transmembrane conductance regulator
Mechanism of Action:15 
Target: cystic fibrosis transmembrane conductance regulator (CFTR)
Action: potentiator
FDA: Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein. In vitro, ivacaftor increased CFTR-mediated transepithelial current (IT) in rodent cells expressing the G551D-CFTR protein following addition of a cyclic adenosine monophosphate (cAMP) agonist with an EC50 of 100 ± 47 nM; however, ivacaftor did not increase IT in the absence of cAMP agonist. Ivacaftor also increased IT in human bronchial epithelial cells expressing G551D-CFTR protein following addition of a cAMP agonist by 10-fold with an EC50 of 236 ± 200 nM. Ivacaftor increased the open probability of G551D-CFTR protein in single channel patch clamp experiments using membrane patches from rodent cells expressing G551D-CFTR protein by 6-fold versus untreated cells after addition of PKA and ATP. In addition to G551D-CFTR, ivacaftor increased the channel-open probability of other mutant CFTR forms expressed in rodent cells, resulting in enhanced CFTR-mediated IT. These mutant CFTR forms included G178R-, S549N-, S549R-, G551S-, G970R-, G1244E-, S1251N-, S1255P-, and G1349D-CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has low channel-open probability (gating) and reduced channel current amplitude (conductance) compared to normal CFTR. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.

Drugs for Retinoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 133)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Vincristineapproved, investigationalPhase 4, Phase 3, Phase 28632068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
2
Itraconazoleapproved, investigationalPhase 413484625-61-655283
Synonyms:
(+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one
(+/-)-1-[( R *)- sec -butyl]-4-[ p -[4-[ p -[[(2 R *,4 S *)-2-(2,4-dichlorophenyl)-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-(DELTA) 2 1,2,4-triazolin-5-one mixture with (+/-)-1-[( R *)- sec -butyl]-4-[ p -[4- [ p -[[(2 S *,4 R *)-2-(2,4-dichlorophenyl)-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl] phenyl]-(DELTA) 2 -1,2,4-triazolin-5-one
(1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one
2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)
4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
84604-65-9
84625-61-6
AC-542
AC1L1GQ5
AC1L1IRU
AC1OCEL7
AC1Q6EZ3
AKOS000280875
Ambap84625-61-6
BIDD:GT0796
BRN 6042047
C35H38Cl2N8O4
CHEBI:6076
CHEMBL22587
CHEMBL882
CID3793
CID55283
CID6917738
CID9961741
CPD000058959
Canadiol
D00350
DB01167
EINECS 283-347-2
FT-0082511
HMS2051K14
HMS2090M20
Hyphanox
I01-1043
I0732
ITC
ITCZ
ITZ
Intraconazole
 
Itraconazol
Itraconazol [Spanish]
Itraconazole
Itraconazole & Bovine Lactoferrin
Itraconazole & Nyotran
Itraconazole & Nyotran(Liposomal Nystatin)
Itraconazole (JAN/USAN)
Itraconazole [USAN:BAN:INN:JAN]
Itraconazole oral solution
Itraconazolum
Itraconazolum [Latin]
Itrizole
Itrizole (TN)
Itrizole (tn)
LS-1843
MLS000028582
MLS000759472
MLS000863291
MLS001148245
MolPort-000-883-864
MolPort-003-848-295
NCGC00089812-03
Onmel
Oriconazole
Oriconazole, R51211, Sporanox
Orungal
Prokanazol
R 51211
R-51211
S2476_Selleck
SAM001246679
SMR000058959
Sempera
Spherazole
Sporal
Sporanos
Sporanox
Sporanox (TN)
Sporanox (tn)
Sporonox
TL8005525
Triasporn
UNII-304NUG5GF4
cis-Itraconazole
itraconazole
3
EtoposideapprovedPhase 4, Phase 3, Phase 2, Phase 1116933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
 
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide Phosphate
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
4
Miconazoleapproved, investigationalPhase 4, Phase 2, Phase 1302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
5
CarboplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
6Ginsengapproved, nutraceuticalPhase 4, Phase 28750647-08-0
7Etoposide phosphatePhase 4, Phase 3, Phase 2, Phase 11169
8Bone Density Conservation AgentsPhase 4, Phase 22600
9Antineoplastic Agents, PhytogenicPhase 4, Phase 3, Phase 2, Phase 14294
10Ibandronic acidPhase 479
11
CurcuminPhase 4124458-37-7969516
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. Natural Yellow 3
CI Natural Yellow 3
Cucurmin
Curcuma
Curcumin
Curcumin I
Diferaloylmethane
Diferuloylmethane
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
Hydrastis
 
Indian saffron
Indian turmeric
Kacha haldi
Kurkumin [czech]
Merita earth
Natural yellow 3
Orange root
Safran D'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yo-kin
Zlut prirodni 3 [Czech]
12Antimitotic AgentsPhase 4, Phase 3, Phase 2, Phase 14296
13HydroxyitraconazolePhase 4134
14Liver ExtractsPhase 4, Phase 2, Phase 13572
15DiphosphonatesPhase 4381
16Anti-Infective AgentsPhase 4, Phase 2, Phase 1, Phase 017220
17Antifungal AgentsPhase 4, Phase 2, Phase 13015
18Tubulin ModulatorsPhase 4, Phase 3, Phase 2, Phase 14279
19Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 19988
20Cytochrome P-450 CYP3A InhibitorsPhase 41421
21Topoisomerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 14081
22HormonesPhase 4, Phase 2, Phase 111748
23Cytochrome P-450 Enzyme InhibitorsPhase 43036
24Hormone AntagonistsPhase 4, Phase 2, Phase 110002
25
AllantoinNutraceuticalPhase 4897-59-6204
Synonyms:
(S)-allantoin
2,5-Dioxo-4-imidazolidinyl-urea
4-Ureido-2,5-Imidazolidinedione
5-Ureido-Hydantoin
5-Ureidohydantoin
5-Ureidohydrantoin
AVC/Dienestrolcream
Alantan
Allantoin
Allantol
 
Alloxantin
Cordianine
D00121
Fancol TOIN
Glyoxyldiureid
Glyoxyldiureide
Glyoxylic diureide
N-(2,5-Dioxo-4-imidazolidinyl)urea
Psoralon
Sebical
Septalan
26
Topotecanapproved, investigationalPhase 3, Phase 2, Phase 1330119413-54-660700
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
123948-87-8
9-Dimethylaminomethyl-10-hydroxycamptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
LS-127395
MLS000759456
 
NCGC00178695-01
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
NChemBio.2007.10-comp24
NSC609699
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SMP2_000312
SMP2_000327
SMR000466344
TOPO
TOPOTECAN, HYCAMTIN
TPT
TTC
Topotecan
Topotecan (BAN)
Topotecan Hcl
Topotecan Hydrochloride
Topotecan Lactone
Topotecan Monohydrochloride, (S)-Isomer
Topotecan [INN:BAN]
Topotecan lactone
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
UNII-7M7YKX2N15
topotecan
27
Cyclophosphamideapproved, investigationalPhase 3, Phase 2, Phase 1, Phase 0264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
28
ThiotepaapprovedPhase 3, Phase 2, Phase 120552-24-45453
Synonyms:
 
Thioplex
29
CisplatinapprovedPhase 3, Phase 2254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
30
Doxorubicinapproved, investigationalPhase 3, Phase 2158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
31
DoxilApproved June 1999Phase 3, Phase 2158231703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
32Immunosuppressive AgentsPhase 3, Phase 2, Phase 1, Phase 010422
33
IodinePhase 3, Phase 2, Phase 14947553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
34cadexomer iodinePhase 3, Phase 2, Phase 1456
35topoisomerase I inhibitorsPhase 3, Phase 2, Phase 11131
36
MesnaPhase 3, Phase 2, Phase 12433375-50-6598
Synonyms:
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
 
CoM
Coenzyme M
HS-CoM
37Antineoplastic Agents, AlkylatingPhase 3, Phase 2, Phase 1, Phase 03406
38Alkylating AgentsPhase 3, Phase 2, Phase 1, Phase 03582
39Immunologic FactorsPhase 3, Phase 2, Phase 1, Phase 018483
40Adjuvants, ImmunologicPhase 3, Phase 2, Phase 11783
41Antirheumatic AgentsPhase 3, Phase 2, Phase 1, Phase 08496
42AnestheticsPhase 3, Phase 27385
43Anti-Bacterial AgentsPhase 3, Phase 2, Phase 1, Phase 09140
44lenograstimPhase 3, Phase 2, Phase 11134
45Antibiotics, AntitubercularPhase 3, Phase 2, Phase 15971
46
PalbociclibapprovedPhase 2, Phase 185571190-30-211431660, 5005498
Synonyms:
2euf
571190-30-2
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
AC1NS8RV
CHEMBL189963
CID5330286
EC-000.2350
 
Kinome_3823
Kinome_3824
LQQ
PD 0332991
PD 332991, PD 0332991, PD0332991
PD-0332991
PD-332991
PD0332991
Palbociclib
Palbociclib Isethionate
S1116_Selleck
47
Dexamethasoneapproved, investigationalPhase 2190950-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Baycadron
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
 
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone sodium phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamethsone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
Ozurdex
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
48
Arsenic trioxideapproved, investigationalPhase 21151327-53-3518740
Synonyms:
28380-38-3
AC1L24QX
AI3-01163
Acide Arsenieux
Acide Arsenieux [French]
Acide arsenieux [French]
Anhydride Arsenieux
Anhydride Arsenieux [French]
Anhydride arsenieux [French]
Arseni Trioxydum
Arseni trioxydum
Arsenic Blanc
Arsenic Blanc [French]
Arsenic Oxide
Arsenic Oxidearsenous Trioxide
Arsenic Sesquioxide
Arsenic Trioxide [UN1561] [Poison]
Arsenic blanc [French]
Arsenic oxide (As2O3)
Arsenic trioxide (JP15/USAN)
Arsenic trioxide [JAN]
Arsenic trioxide [UN1561] [Poison]
Arsenic(III) trioxide
Arsenic, White
Arsenicum Album
Arsenigen Saure
Arsenigen Saure [German]
Arsenigen saure [German]
Arsenious Acid
Arsenious Acid Anhydride
Arsenious Oxide
Arsenious Trioxide
Arsenious trioxide
Arsenite
Arsenolite
Arsenous Acid
Arsenous Acid Anhydride
Arsenous Anhydride
 
Arsenous Oxide
Arsenous Oxide Anhydride
Arsenous oxide [ISO]
Arsenox
Arsentrioxide
Arsodent
C006632
CCRIS 5455
CHEMBL405991
CID14888
Caswell No. 059
Claudelite
Claudetite
Crude Arsenic
D02106
Di-Arsenic Trioxide
Diarsenic Trioxide
Diarsonic Trioxide
EINECS 215-481-4
EPA Pesticide Chemical Code 007001
HSDB 419
LS-761
MolPort-006-823-587
Oxyde Arsenieux
Oxyde Arsenieux [ISO-French]
Poison Flour
RCRA waste no. P012
Rcra waste number P012
Trisenox
Trisenox (TN)
Trixenox
UN 1561
UN1561
UNII-S7V92P67HO
White Arsenic
arsenic trioxide
arsenic(3+)
naonobin
oxygen(2-)
49
MelphalanapprovedPhase 1, Phase 2685148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
Levofalan
 
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan Hydrochloride
Melphalan [USAN:INN:BAN:JAN]
Melphalan hydrochloride
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
50
RanibizumabapprovedPhase 2, Phase 1460347396-82-1459903
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
 
Ranibizumab
Ranibizumab (USAN/INN)
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
ranibizumab
rhuFab V2

Interventional clinical trials:

(show top 50)    (show all 100)
idNameStatusNCT IDPhase
1CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular RetinoblastomaCompletedNCT02319486Phase 4
2Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell TransplantationCompletedNCT00336531Phase 4
3Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate SupplementationCompletedNCT02249741Phase 4
4The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile DysfunctionCompletedNCT02413099Phase 4
5Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical StudyCompletedNCT02204826Phase 4
6Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular RetinoblastomaCompletedNCT00072384Phase 3
7Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed RetinoblastomaCompletedNCT00335738Phase 3
8Carboplatin Periocular Injection for RetinoblastomaRecruitingNCT02137928Phase 3
9Adjuvant Chemotherapy for High-risk Retinoblastoma After EnucleationRecruitingNCT01906814Phase 3
10Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With CancerRecruitingNCT01987596Phase 3
11Does Posterior Reconstruction of the Rhabdosphincter Improve Early Recovery of Continence After Robotic-Assisted Radical Prostatectomy?RecruitingNCT01809522Phase 3
12Study of Treatment for Patients With Cancer of the Eye -RetinoblastomaActive, not recruitingNCT00186888Phase 3
13Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular RetinoblastomaActive, not recruitingNCT00079417Phase 3
14Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular RetinoblastomaActive, not recruitingNCT00554788Phase 3
15Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With RetinoblastomaCompletedNCT00004006Phase 2
16Intra-arterial Chemotherapy(Chemosurgery) for RetinoblastomaCompletedNCT00901238Phase 1, Phase 2
17Chemotherapy in Treating Patients With RetinoblastomaCompletedNCT00002675Phase 2
18Carboplatin Plus Vincristine in Treating Children With RetinoblastomaCompletedNCT00002794Phase 2
19Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid TumorsCompletedNCT00024258Phase 2
20Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00006102Phase 2
21Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00831844Phase 2
22High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid TumorsCompletedNCT00003173Phase 2
23Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare CancerCompletedNCT00002515Phase 2
24Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.CompletedNCT01291017Phase 2
25An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.CompletedNCT00555906Phase 2
26Protocol for the Study and Treatment of Participants With Intraocular RetinoblastomaRecruitingNCT01783535Phase 2
27Intra-arterial Chemotherapy for Children With RetinoblastomaRecruitingNCT00906113Phase 1, Phase 2
28Intra-arterial Chemotherapy for the Treatment of Intraocular RetinoblastomaRecruitingNCT01293539Phase 2
29Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From GuatemalaRecruitingNCT01857752Phase 2
30Efficacy Study of Lucentis in the Treatment of RetinoblastomaRecruitingNCT01899066Phase 2
31Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal CancerRecruitingNCT00445965Phase 2
32Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line ChemotherapyRecruitingNCT02334527Phase 2
33A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate CancerRecruitingNCT02059213Phase 2
34A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation TherapyRecruitingNCT02607124Phase 1, Phase 2
35Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB ExpressionRecruitingNCT02555189Phase 1, Phase 2
36Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung CancerRecruitingNCT02487095Phase 1, Phase 2
37Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibRecruitingNCT01907607Phase 2
38PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC TrialRecruitingNCT02624973Phase 2
39Chemotherapy Treatment for Children With Intraocular Germ-Line RetinoblastomaActive, not recruitingNCT00179920Phase 2
40Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral RetinoblastomaActive, not recruitingNCT00110110Phase 2
41Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular DementiaActive, not recruitingNCT01761227Phase 2
42Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast CancerActive, not recruitingNCT00721409Phase 1, Phase 2
43Proton Beam Radiation Therapy for Intraocular and Periocular RetinoblastomaTerminatedNCT00432445Phase 2
44Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular StageTerminatedNCT01393769Phase 2
45A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)TerminatedNCT01919229Phase 2
46Intra-arterial Chemotherapy for Advanced Intraocular RetinoblastomaWithdrawnNCT01151748Phase 2
47Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain TumorWithdrawnNCT00003273Phase 2
48Phase I Trial of Periocular Topotecan in RetinoblastomaCompletedNCT00460876Phase 1
49Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal CancerCompletedNCT00003022Phase 1
50Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine FeaturesCompletedNCT01048892Phase 1

Search NIH Clinical Center for Retinoblastoma

Inferred drug relations via UMLS65/NDF-RT43:

Genetic Tests for Retinoblastoma

About this section

Genetic tests related to Retinoblastoma:

id Genetic test Affiliating Genes
1 Retinoblastoma22 RB1

Anatomical Context for Retinoblastoma

About this section

MalaCards organs/tissues related to Retinoblastoma:

33
Eye, Retina, Breast, Prostate, Lung, Bone, Pineal

FMA organs/tissues related to Retinoblastoma:

16
The pineal or suprasellar region

Animal Models for Retinoblastoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Retinoblastoma:

38 (show all 17)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053819.6CDK4, E2F1, E2F3, E2F4, MDM2, RB1
2MP:00053699.5CDK4, E2F1, HDAC1, MDM2, RB1, RBL1
3MP:00053889.4ARID4A, E2F1, E2F3, E2F4, HDAC1, RB1
4MP:00053899.3ARID4A, CDK4, E2F1, E2F3, E2F4, MDM2
5MP:00028739.1CDK4, E2F1, E2F3, E2F4, HDAC1, KDM5A
6MP:00053909.1ARID4A, E2F1, E2F3, E2F4, MDM2, RB1
7MP:00107719.1ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
8MP:00053869.0ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
9MP:00053799.0ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
10MP:00053858.7ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
11MP:00020068.7ARID4A, CDK4, E2F1, E2F4, HDAC1, KDM5A
12MP:00053808.6CDK4, E2F1, E2F3, E2F4, HDAC1, MDM2
13MP:00053978.4ARID4A, CDK4, E2F1, E2F4, HDAC1, KDM5A
14MP:00053848.4ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
15MP:00053878.3ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
16MP:00053788.2ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
17MP:00107687.9ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1

Publications for Retinoblastoma

About this section

Articles related to Retinoblastoma:

(show top 50)    (show all 2317)
idTitleAuthorsYear
1
Inhibitor of DNA Binding 4 (ID4) is highly expressed in human melanoma tissues and may function to restrict normal differentiation of melanoma cells. (25642713)
2015
2
Analysis of relative expression level of VEGF ( vascular endothelial growth factor ), HIF-1I+ ( hypoxia inducible factor 1I+ ) and CTGF ( connective tissue growth factor ) genes in chronic glomerulonephritis (CGN) patients. (24577260)
2013
3
Nitrosative stress in human skeletal muscle attenuated by exercise countermeasure after chronic disuse. (24251120)
2013
4
EZH2 promotes a bi-lineage identity in basal-like breast cancer cells. (22986524)
2013
5
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. (22056852)
2012
6
Electrostatic modifications of the human leukocyte antigen DR P9 peptide-binding pocket in primary sclerosing cholangitis: back to the future with human leukocyte antigen DRI^. (21538433)
2011
7
Sensory profile in primary restless legs syndrome and restless legs syndrome associated with small fibre neuropathy. (21059747)
2011
8
Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression. (21098292)
2010
9
The human WW45 protein enhances MST1-mediated apoptosis in vivo. (19212654)
2009
10
Chikungunya: an emerging and spreading arthropod-borne viral disease. (20009275)
2009
11
GSTM1-null polymorphism as possible risk marker for hypertension: results from the aging and longevity study in the Sirente Geographic Area (ilSIRENTE study). (18840420)
2009
12
Viral inhibitor of apoptosis vFLIP/K13 protects endothelial cells against superoxide-induced cell death. (18987137)
2009
13
IL-17 stimulates migration of carotid artery vascular smooth muscle cells in an MMP-9 dependent manner via p38 MAPK and ERK1/2-dependent NF-kappaB and AP-1 activation. (19404732)
2009
14
Prostaglandin F2alpha synthase activities of aldo-keto reductase 1B1, 1B3 and 1B7. (19010934)
2009
15
Lymphangiogenesis in gastric carcinoma correlates with prognosis. (19224540)
2009
16
Endoscopic frontal sinus septectomy in the treatment of unilateral frontal sinusitis: revisiting an open technique. (19958729)
2009
17
Ruptured aneurysm of the sinus of Valsalva with Wildervanck syndrome (cervico-oculo-acoustic syndrome), blepharoptosis and short stature: case report. (17721033)
2007
18
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. (17545613)
2007
19
Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE. (17515539)
2007
20
Dermatomyositis, lobar panniculitis and inflammatory myopathy with abundant macrophages. (16809038)
2006
21
Long-QT syndrome-related sodium channel mutations probed by the dynamic action potential clamp technique. (16254012)
2006
22
Involvement of nonlamellar-prone lipids in the stability increase of human cytochrome P450 1A2 in reconstituted membranes. (15966743)
2005
23
Genetic variation in uncoupling protein 3 is associated with dietary intake and body composition in females. (15045692)
2004
24
A broad but restricted requirement for TAF-5 (human TAFII100) for embryonic transcription in Caenorhabditis elegans. (12458202)
2003
25
Platelet APP isoform ratios in asymptomatic young adults expressing an AD-related presenilin-1 mutation. (11166800)
2001
26
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. (11410517)
2001
27
Serum concentration of adhesion molecules in patients with delayed ischaemic neurological deficit after aneurysmal subarachnoid haemorrhage: the immunoglobulin and selectin superfamilies. (11511705)
2001
28
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. (10918610)
2000
29
Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. (10749795)
2000
30
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. (11071371)
2000
31
Assignment of the human slit homologue SLIT2 to human chromosome band 4p15.2. (10575218)
1999
32
Particulate matter initiates inflammatory cytokine release by activation of capsaicin and acid receptors in a human bronchial epithelial cell line. (9882597)
1999
33
Lagophthalmos in leprosy. (9598404)
1998
34
Leukemia inhibitory factor induces the 85-kDa cytosolic phospholipase A2 gene expression in cultured human bronchial epithelial cells. (9042332)
1997
35
Defective myosin VIIA gene responsible for Usher syndrome type 1B. (7870171)
1995
36
Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. (8526243)
1995
37
The interaction of auranofin and buthionine sulfoximine blocks activation of human peripheral T lymphocytes. (8242758)
1993
38
Ainhum. (7418704)
1980
39
Production by EBV infection of an EBNA-positive subline from an EBNA-negative human lymphoma cell line without detectable EBV DNA. (170210)
1975
40
41
42
43
44
45
46
47
48
49
50

Variations for Retinoblastoma

About this section

UniProtKB/Swiss-Prot genetic disease variations for Retinoblastoma:

67 (show all 22)
id Symbol AA change Variation ID SNP ID
1RB1p.Glu72GlnVAR_005572
2RB1p.Glu137AspVAR_005573
3RB1p.Ile185ThrVAR_005574
4RB1p.Arg358GlnVAR_005575
5RB1p.Met457ArgVAR_005576
6RB1p.His549TyrVAR_005578
7RB1p.Ser567LeuVAR_005579
8RB1p.Ala635ProVAR_005580
9RB1p.Val654GluVAR_005581
10RB1p.Arg661TrpVAR_005582
11RB1p.Leu662ProVAR_005583
12RB1p.His673ProVAR_005584
13RB1p.Gln685ProVAR_005585
14RB1p.Cys706TyrVAR_005586
15RB1p.Cys712ArgVAR_005587
16RB1p.Asn803LysVAR_005588
17RB1p.Arg358GlyVAR_010046
18RB1p.Lys447GlnVAR_010048
19RB1p.Lys530ArgVAR_010049
20RB1p.Leu657ProVAR_010050
21RB1p.Arg500GlyVAR_011580
22RB1p.Lys616GluVAR_011581

Clinvar genetic disease variations for Retinoblastoma:

5 (show all 95)
id Gene Variation Type Significance SNP ID Assembly Location
1RB1NM_000321.2(RB1): c.1723C> T (p.Gln575Ter)single nucleotide variantPathogenicrs587778864GRCh37Chr 13, 49027156: 49027156
2RB1NM_000321.2(RB1): c.1735C> T (p.Arg579Ter)single nucleotide variantPathogenicrs121913305GRCh37Chr 13, 49027168: 49027168
3RB1NM_000321.2(RB1): c.1738G> T (p.Glu580Ter)single nucleotide variantPathogenicrs587778858GRCh37Chr 13, 49027171: 49027171
4RB1NG_009009.1: g.154289dupAduplicationPathogenic
5RB1NM_000321.2(RB1): c.1909C> T (p.Gln637Ter)single nucleotide variantPathogenicrs587778833GRCh37Chr 13, 49030434: 49030434
6RB1NM_000321.2(RB1): c.1925T> A (p.Leu642Ter)single nucleotide variantPathogenicrs587778865GRCh37Chr 13, 49030450: 49030450
7RB1NM_000321.2(RB1): c.1927A> G (p.Lys643Glu)single nucleotide variantPathogenicrs587778866GRCh37Chr 13, 49030452: 49030452
8RB1NM_000321.2(RB1): c.1960+5G> Asingle nucleotide variantPathogenicrs587778871GRCh37Chr 13, 49030490: 49030490
9RB1NM_000321.2(RB1): c.1961-2A> Tsingle nucleotide variantPathogenicrs587778867GRCh37Chr 13, 49033822: 49033822
10RB1NM_000321.2(RB1): c.1973C> A (p.Ala658Asp)single nucleotide variantPathogenicrs587778834GRCh37Chr 13, 49033836: 49033836
11RB1NM_000321.2(RB1): c.2101G> A (p.Asp701Asn)single nucleotide variantPathogenicrs587778859GRCh37Chr 13, 49033964: 49033964
12RB1NM_000321.2(RB1): c.2107-1G> Csingle nucleotide variantPathogenicrs587778860GRCh37Chr 13, 49037866: 49037866
13RB1NM_000321.2(RB1): c.2164A> T (p.Lys722Ter)single nucleotide variantPathogenicrs587778849GRCh37Chr 13, 49037924: 49037924
14RB1NM_000321.2(RB1): c.2197C> T (p.His733Tyr)single nucleotide variantPathogenicrs587778835GRCh37Chr 13, 49037957: 49037957
15RB1NM_000321.2(RB1): c.2209G> T (p.Glu737Ter)single nucleotide variantPathogenicrs587778868GRCh37Chr 13, 49037969: 49037969
16RB1NG_009009.1: g.1662319T> Asingle nucleotide variantPathogenic
17RB1NM_000321.2(RB1): c.2227_2230dupTTGA (p.Lys745Aspfs)duplicationPathogenicrs587778836GRCh37Chr 13, 49039149: 49039152
18RB1NM_000321.2(RB1): c.2247T> A (p.Tyr749Ter)single nucleotide variantPathogenicrs587778861GRCh37Chr 13, 49039169: 49039169
19RB1NG_009009.1: g.166501C> Gsingle nucleotide variantPathogenic
20RB1NM_000321.2(RB1): c.2453delG (p.Gly818Valfs)deletionPathogenicrs587778837GRCh37Chr 13, 49039468: 49039468
21RB1NM_000321.2(RB1): c.2490-1G> Asingle nucleotide variantPathogenicrs587778838GRCh37Chr 13, 49047495: 49047495
22RB1NM_000321.2(RB1): c.2520+1G> Asingle nucleotide variantPathogenicrs587778850GRCh37Chr 13, 49047527: 49047527
23RB1NM_000321.2(RB1): c.2525dupC (p.Glu843Terfs)duplicationPathogenicrs587778851GRCh37Chr 13, 49050841: 49050841
24RB1NM_000321.2(RB1): c.2663+2T> Csingle nucleotide variantPathogenicrs587778839GRCh37Chr 13, 49050981: 49050981
25RB1NM_000321.2(RB1): c.305_306delGT (p.Cys102Tyrfs)deletionPathogenicrs587778825GRCh37Chr 13, 48916775: 48916776
26RB1NM_000321.2(RB1): c.409G> T (p.Glu137Ter)single nucleotide variantPathogenicrs121913296GRCh37Chr 13, 48919244: 48919244
27RB1NM_000321.2(RB1): c.438_441delTGCT (p.Asn146Lysfs)deletionPathogenicrs587778841GRCh37Chr 13, 48919273: 48919276
28RB1NM_000321.2(RB1): c.446C> G (p.Ser149Ter)single nucleotide variantPathogenicrs587778870GRCh37Chr 13, 48919281: 48919281
29RB1NM_000321.2(RB1): c.463dupT (p.Tyr155Leufs)duplicationPathogenicrs587778854GRCh37Chr 13, 48919298: 48919298
30RB1NM_000321.2(RB1): c.508G> T (p.Glu170Ter)single nucleotide variantPathogenicrs587778826GRCh37Chr 13, 48921968: 48921968
31RB1NG_009009.1: g.5168-?_5303+?(2)undetermined variantPathogenic
32RB1NM_000321.2(RB1): c.72_74delGCC (p.Pro29del)deletionPathogenicrs587778823GRCh37Chr 13, 48878120: 48878122
33RB1NM_000321.2(RB1): c.103C> T (p.Gln35Ter)single nucleotide variantPathogenicrs587778869GRCh37Chr 13, 48878151: 48878151
34RB1NG_009009.1: g.5279_5281delGCCInsCTinsertionPathogenic
35RB1NM_000321.2(RB1): c.763C> T (p.Arg255Ter)single nucleotide variantPathogenicrs587778842GRCh37Chr 13, 48936995: 48936995
36RB1NM_000321.2(RB1): c.795delA (p.Lys265Asnfs)deletionPathogenicrs587778827GRCh37Chr 13, 48937027: 48937027
37RB1NM_000321.2(RB1): c.884dupA (p.Asn295Lysfs)duplicationPathogenicrs587778828GRCh37Chr 13, 48939052: 48939052
38RB1NM_000321.2(RB1): c.937G> T (p.Glu313Ter)single nucleotide variantPathogenicrs587778843GRCh37Chr 13, 48939105: 48939105
39RB1NM_000321.2(RB1): c.958C> T (p.Arg320Ter)single nucleotide variantPathogenicrs121913300GRCh37Chr 13, 48941648: 48941648
40RB1NM_000321.2(RB1): c.1021A> T (p.Lys341Ter)single nucleotide variantPathogenicrs587778855GRCh37Chr 13, 48941711: 48941711
41RB1NM_000321.2(RB1): c.1024delA (p.Thr342Leufs)deletionPathogenicrs587778844GRCh37Chr 13, 48941714: 48941714
42RB1NM_000321.2(RB1): c.1049+1G> Asingle nucleotide variantPathogenicrs587776782GRCh37Chr 13, 48941740: 48941740
43RB1NM_000321.2(RB1): c.1060_1061delCA (p.Gln354Glufs)deletionPathogenicrs587778829GRCh37Chr 13, 48942673: 48942674
44RB1NM_000321.2(RB1): c.1147dupC (p.Gln383Profs)duplicationPathogenicrs587778830GRCh37Chr 13, 48947560: 48947560
45RB1NM_000321.2(RB1): c.1166T> A (p.Leu389Ter)single nucleotide variantPathogenicrs587778845GRCh37Chr 13, 48947579: 48947579
46RB1NM_000321.2(RB1): c.1215+1G> Asingle nucleotide variantPathogenicrs587776783GRCh37Chr 13, 48947629: 48947629
47RB1NM_000321.2(RB1): c.1216-1G> Asingle nucleotide variantPathogenicrs587778831GRCh37Chr 13, 48951053: 48951053
48RB1NM_000321.2(RB1): c.1332+1G> Asingle nucleotide variantPathogenicrs587778846GRCh37Chr 13, 48951171: 48951171
49RB1NM_000321.2(RB1): c.1332+1G> Tsingle nucleotide variantPathogenicrs587778846GRCh37Chr 13, 48951171: 48951171
50RB1NM_000321.2(RB1): c.1346G> T (p.Gly449Val)single nucleotide variantPathogenicrs587778847GRCh37Chr 13, 48953743: 48953743
51RB1NM_000321.2(RB1): c.1363C> T (p.Arg455Ter)single nucleotide variantPathogenicrs121913302GRCh37Chr 13, 48953760: 48953760
52RB1NM_000321.2(RB1): c.1456_1457delTT (p.Leu486Ilefs)deletionPathogenicrs587778832GRCh37Chr 13, 48954335: 48954336
53RB1NM_000321.2(RB1): c.1472T> C (p.Leu491Pro)single nucleotide variantPathogenicrs587778848GRCh37Chr 13, 48954351: 48954351
54RB1NM_000321.2(RB1): c.1654C> T (p.Arg552Ter)single nucleotide variantPathogenicrs121913303GRCh37Chr 13, 48955538: 48955538
55RB1NM_000321.2(RB1): c.1688G> A (p.Trp563Ter)single nucleotide variantPathogenicrs587778863GRCh37Chr 13, 48955572: 48955572
56RB1NM_000321.2(RB1): c.1695+1G> Asingle nucleotide variantPathogenicrs587778857GRCh37Chr 13, 48955580: 48955580
57RB1NM_000321.2(RB1): c.217delA (p.Arg73Glufs)deletionPathogenicrs587778840GRCh37Chr 13, 48881495: 48881495
58RB1NM_000321.2(RB1): c.219_220delAG (p.Arg73Serfs)deletionPathogenicrs587778862GRCh37Chr 13, 48881497: 48881498
59RB1NM_000321.2(RB1): c.227_228dupTA (p.Thr77Terfs)duplicationPathogenicrs587778824GRCh37Chr 13, 48881505: 48881506
60RB1NM_000321.2(RB1): c.2520+1deldeletionPathogenicrs587776779GRCh37Chr 13, 49047527: 49047527
61RB1NM_000321.2(RB1): c.1960+2T> Csingle nucleotide variantPathogenicrs587776780GRCh37Chr 13, 49030487: 49030487
62RB1NM_000321.2(RB1): c.1333C> T (p.Arg445Ter)single nucleotide variantPathogenicrs3092891GRCh37Chr 13, 48953730: 48953730
63RB1NM_000321.2(RB1): c.1700C> T (p.Ser567Leu)single nucleotide variantPathogenicrs137853292GRCh37Chr 13, 49027133: 49027133
64RB1NM_000321.2(RB1): c.2359C> T (p.Arg787Ter)single nucleotide variantPathogenicrs137853293GRCh37Chr 13, 49039374: 49039374
65RB1NM_000321.2(RB1): c.2244delG (p.Glu748Aspfs)deletionPathogenicrs587776781GRCh37Chr 13, 49039166: 49039166
66RB1NM_000321.2(RB1): c.1049+1G> Tsingle nucleotide variantPathogenicrs587776782GRCh37Chr 13, 48941740: 48941740
67RB1NM_000321.2(RB1): c.1072C> T (p.Arg358Ter)single nucleotide variantPathogenicrs121913301GRCh37Chr 13, 48942685: 48942685
68RB1RB1, 5-BP DEL, EX8deletionPathogenic
69RB1NM_000321.2(RB1): c.979_1033dup55 (p.Thr345Lysfs)duplicationPathogenicGRCh37Chr 13, 48941669: 48941723
70RB1NM_000321.2(RB1): c.1760_1769delAATCTGCTTG (p.Glu587Valfs)deletionPathogenicrs587776784GRCh37Chr 13, 49027193: 49027202
71RB1NM_000321.2(RB1): c.1949_1957delTTTATAAAA (p.Phe650_Lys928del)deletionPathogenicrs587776785GRCh37Chr 13, 49030474: 49030482
72RB1NM_000321.2(RB1): c.2212-1G> Asingle nucleotide variantPathogenicrs587776786GRCh37Chr 13, 49039133: 49039133
73RB1NM_000321.2(RB1): c.-189G> Tsingle nucleotide variantPathogenicrs387906520GRCh37Chr 13, 48877860: 48877860
74RB1NM_000321.2(RB1): c.-198G> Asingle nucleotide variantPathogenicrs387906521GRCh37Chr 13, 48877851: 48877851
75RB1NM_000321.2(RB1): c.1981C> T (p.Arg661Trp)single nucleotide variantPathogenicrs137853294GRCh37Chr 13, 49033844: 49033844
76RB1RB1, GLN675TERsingle nucleotide variantPathogenic
77RB1NM_000321.2(RB1): c.2211G> A (p.Glu737=)single nucleotide variantPathogenicrs587776787GRCh37Chr 13, 49037971: 49037971
78RB1NM_000321.2(RB1): c.1666C> T (p.Arg556Ter)single nucleotide variantPathogenicrs121913304GRCh37Chr 13, 48955550: 48955550
79RB1NM_000321.2(RB1): c.1439_1441delACA (p.Asn480del)deletionPathogenicrs587776788GRCh37Chr 13, 48954318: 48954320
80RB1NM_000321.2(RB1): c.2134T> C (p.Cys712Arg)single nucleotide variantPathogenicrs137853296GRCh37Chr 13, 49037894: 49037894
81RB1NM_000321.2(RB1): c.607+1G> Tsingle nucleotide variantPathogenicrs587776789GRCh37Chr 13, 48923160: 48923160
82RB1NM_000321.2(RB1): c.1818T> A (p.Tyr606Ter)single nucleotide variantPathogenicrs137853297GRCh37Chr 13, 49030343: 49030343
83RB1NM_000321.2(RB1): c.43_65dup23 (p.Pro23Leufs)duplicationPathogenicrs587776790GRCh37Chr 13, 48878091: 48878113
84RB1NM_000321.2(RB1): c.2490-1398A> Gsingle nucleotide variantPathogenicrs587776791GRCh37Chr 13, 49046098: 49046098
85RB1NM_000321.2(RB1): c.1421+12_1421+32deldeletionPathogenicrs587781256GRCh37Chr 13, 48954232: 48954252
86RB1NM_000321.2(RB1): c.1907delT (p.Phe636Serfs)deletionPathogenicrs587781257GRCh37Chr 13, 49030432: 49030432
87RB1NM_000321.2(RB1): c.54_79del26 (p.Glu19Profs)deletionPathogenicrs727504120GRCh37Chr 13, 48878102: 48878127
88RB1NM_000321.2(RB1): c.1191delA (p.Glu398Lysfs)deletionPathogenicrs727504121GRCh37Chr 13, 48947604: 48947604
89RB1NM_000321.2(RB1): c.1401_1411dupATTATCCATTC (p.Gln471Hisfs)duplicationPathogenicrs797044649GRCh37Chr 13, 48954200: 48954210
90RB1NM_000321.2(RB1): c.1696-1G> Asingle nucleotide variantPathogenicrs794727199GRCh37Chr 13, 49027128: 49027128
91RB1NM_000321.2(RB1): c.2370C> A (p.Tyr790Ter)single nucleotide variantPathogenicrs794727372GRCh37Chr 13, 49039385: 49039385
92RB1NM_000321.2(RB1): c.297G> A (p.Trp99Ter)single nucleotide variantPathogenicrs794727481GRCh37Chr 13, 48916767: 48916767
93RB1NM_000321.2(RB1): c.1399C> T (p.Arg467Ter)single nucleotide variantPathogenicrs398123331GRCh37Chr 13, 48954198: 48954198
94RB1NM_000321.2(RB1): c.1585dupT (p.Tyr529Leufs)duplicationPathogenicrs398123332GRCh37Chr 13, 48955469: 48955469
95RB1NM_000321.2(RB1): c.2067_2079delGAATGAGTATGAAinsCAC (p.Gln689Hisfs)indelPathogenicrs398123333GRCh37Chr 13, 49033930: 49033942

Cosmic variations for Retinoblastoma:

7 (show top 50)    (show all 180)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM1015RB1eye,retina,retinoblastoma,NS3
2COSM1015RB1eye,retina,retinoblastoma,NS3
3COSM1015RB1eye,retina,retinoblastoma,NS3
4COSM1015RB1eye,retina,retinoblastoma,NS3
5COSM1015RB1eye,retina,retinoblastoma,NS3
6COSM1015RB1eye,retina,retinoblastoma,NS3
7COSM1015RB1eye,retina,retinoblastoma,NS3
8COSM1015RB1eye,retina,retinoblastoma,NS3
9COSM1015RB1eye,retina,retinoblastoma,NS3
10COSM1016RB1eye,retina,retinoblastoma,NS3
11COSM1016RB1eye,retina,retinoblastoma,NS3
12COSM1026RB1eye,retina,retinoblastoma,NS3
13COSM1026RB1eye,retina,retinoblastoma,NS3
14COSM1029RB1eye,retina,retinoblastoma,NS3
15COSM1026RB1eye,retina,retinoblastoma,NS3
16COSM1017RB1eye,retina,retinoblastoma,NS3
17COSM1016RB1eye,retina,retinoblastoma,NS3
18COSM1017RB1eye,retina,retinoblastoma,NS3
19COSM1017RB1eye,retina,retinoblastoma,NS3
20COSM1014RB1eye,retina,retinoblastoma,NS3
21COSM1014RB1eye,retina,retinoblastoma,NS3
22COSM911RB1eye,retina,retinoblastoma,NS3
23COSM936RB1eye,retina,retinoblastoma,NS3
24COSM936RB1eye,retina,retinoblastoma,NS3
25COSM936RB1eye,retina,retinoblastoma,NS3
26COSM911RB1eye,retina,retinoblastoma,NS3
27COSM911RB1eye,retina,retinoblastoma,NS3
28COSM910RB1eye,retina,retinoblastoma,NS3
29COSM910RB1eye,retina,retinoblastoma,NS3
30COSM910RB1eye,retina,retinoblastoma,NS3
31COSM938RB1eye,retina,retinoblastoma,NS3
32COSM938RB1eye,retina,retinoblastoma,NS3
33COSM943RB1eye,retina,retinoblastoma,NS3
34COSM943RB1eye,retina,retinoblastoma,NS3
35COSM1014RB1eye,retina,retinoblastoma,NS3
36COSM943RB1eye,retina,retinoblastoma,NS3
37COSM942RB1eye,retina,retinoblastoma,NS3
38COSM938RB1eye,retina,retinoblastoma,NS3
39COSM942RB1eye,retina,retinoblastoma,NS3
40COSM942RB1eye,retina,retinoblastoma,NS3
41COSM1029RB1eye,retina,retinoblastoma,NS3
42COSM1029RB1eye,retina,retinoblastoma,NS3
43COSM1636648RB1eye,retina,retinoblastoma,NS3
44COSM1636648RB1eye,retina,retinoblastoma,NS3
45COSM3724517RB1eye,retina,retinoblastoma,NS3
46COSM3724517RB1eye,retina,retinoblastoma,NS3
47COSM1636648RB1eye,retina,retinoblastoma,NS3
48COSM144722RB1eye,retina,retinoblastoma,NS3
49COSM13117RB1eye,retina,retinoblastoma,NS3
50COSM144722RB1eye,retina,retinoblastoma,NS3

Expression for genes affiliated with Retinoblastoma

About this section
Search GEO for disease gene expression data for Retinoblastoma.

Pathways for genes affiliated with Retinoblastoma

About this section

Pathways related to Retinoblastoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 57)
idSuper pathwaysScoreTop Affiliating Genes
110.1RB1, RBL1, RBL2
2
Show member pathways
10.0HDAC1, MDM2
310.0E2F1, MDM2, RB1
4
Show member pathways
10.0ARID4A, E2F1, KDM5A
5
Show member pathways
9.9ARID4A, E2F1, KDM5A
69.9HDAC1, RBBP4, RBBP7
79.9HDAC1, RBBP4, RBBP7
89.9HDAC1, RBBP4, RBBP7
99.9CDK4, E2F1, RB1, RBL1
109.9CDK4, E2F1, RB1, RBL2
11
Show member pathways
9.8CDK4, E2F1, MDM2, RB1
12
Show member pathways
9.8CDK4, E2F1, MDM2, RB1
139.8E2F1, HDAC1, RB1, RBBP8
149.8CDK4, E2F1, E2F3, RB1
159.8E2F1, HDAC1, RBBP4, RBBP7
169.8E2F1, E2F4, RB1, RBL1, RBL2
17
Show member pathways
9.7ARID4A, HDAC1, RBBP4, RBBP7
18
Show member pathways
9.7E2F4, HDAC1, RBL1, TFDP1
19
Show member pathways
9.7E2F1, E2F4, RBL1, RBL2, TFDP1
20
Show member pathways
9.6CDK4, E2F1, E2F4, MDM2, RB1
219.6CDK4, E2F1, E2F4, MDM2, RBL1
22
Show member pathways
9.6CDK4, E2F1, E2F3, MDM2, RB1
239.6CDK4, E2F1, E2F3, MDM2, RB1
249.6CDK4, E2F1, HDAC1, MDM2, RB1
259.6E2F1, E2F3, E2F4, RB1, TFDP1
269.5CDK4, E2F1, E2F3, MDM2, TFDP1
27
Show member pathways
9.5CDK4, E2F1, E2F4, RB1, RBL2, TFDP1
289.5CDK4, HDAC1, MDM2, RB1, RBL1, RBL2
299.5E2F1, HDAC1, MDM2, RB1, RBBP4, RBBP7
309.4CDK4, E2F1, E2F3, E2F4, MDM2, RB1
319.4CDK4, HDAC1, RBBP4, RBBP7, RBL1, TFDP1
32
Show member pathways
9.4E2F1, E2F3, E2F4, HDAC1, RB1, RBBP8
33
Show member pathways
9.4E2F4, HDAC1, RB1, RBBP4, RBBP7, RBL1
34
Show member pathways
9.3CDK4, E2F1, E2F3, HDAC1, MDM2, RB1
359.3CDK4, E2F1, E2F3, HDAC1, MDM2, RB1
369.2CDK4, E2F4, HDAC1, RB1, RBL1, RBL2
37
Show member pathways
9.2ARID4A, CDK4, HDAC1, KDM5A, RBBP4, RBBP5
389.2E2F4, HDAC1, KDM5A, MDM2, RB1, RBBP4
39
Show member pathways
9.1CDK4, E2F1, E2F3, E2F4, HDAC1, MDM2
40
Show member pathways
9.1CDK4, E2F1, E2F3, MDM2, RB1, RBBP4
41
Show member pathways
9.1CDK4, E2F1, E2F3, E2F4, MDM2, RB1
42
Show member pathways
8.9CDK4, E2F1, E2F3, E2F4, HDAC1, RB1
438.8E2F1, E2F3, E2F4, HDAC1, RB1, RBBP4
44
Show member pathways
8.8E2F1, E2F4, HDAC1, MDM2, RBBP4, RBBP7
45
Show member pathways
8.7CDK4, E2F1, E2F3, E2F4, HDAC1, RB1
468.7CDK4, E2F1, E2F3, E2F4, HDAC1, MDM2
478.6ARID4A, CDK4, E2F1, E2F3, HDAC1, MDM2
48
Show member pathways
8.6DDX1, E2F1, E2F4, HDAC1, MDM2, RBBP4
49
Show member pathways
8.5CDK4, E2F1, E2F3, E2F4, HDAC1, MDM2
50
Show member pathways
8.2CDK4, E2F1, E2F3, E2F4, HDAC1, MDM2

GO Terms for genes affiliated with Retinoblastoma

About this section

Biological processes related to Retinoblastoma according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1cellular response to xenobiotic stimulusGO:007146610.9E2F1, RB1
2CENP-A containing nucleosome assemblyGO:003408010.8RBBP4, RBBP7
3regulation of lipid kinase activityGO:004355010.8RB1, RBL1, RBL2
4G1/S transition of mitotic cell cycleGO:000008210.4E2F1, RB1, RBBP8
5histone deacetylationGO:001657510.3ARID4A, HDAC1, RBBP4
6regulation of signal transduction by p53 class mediatorGO:190179610.2HDAC1, MDM2, RBBP4, RBBP7
7Notch signaling pathwayGO:000721910.1E2F1, E2F3, HDAC1, TFDP1
8negative regulation of gene expression, epigeneticGO:004581410.0HDAC1, RBBP4, RBBP7
9negative regulation of transcription, DNA-templatedGO:004589210.0ARID4A, E2F1, RB1, RBBP7
10positive regulation of transcription, DNA-templatedGO:004589310.0E2F1, E2F3, HDAC1, KDM5A, RB1
11DNA replicationGO:00062609.9RBBP4, RBBP6, RBBP7, RBBP8
12mitotic cell cycleGO:00002789.8E2F1, E2F4, RB1, RBBP4, RBL1, TFDP1
13gene expressionGO:00104679.8DDX1, E2F4, HDAC1, RBBP4, RBL1
14regulation of cell cycleGO:00517269.6CDK4, E2F1, RB1, RBBP4, RBL1, RBL2
15positive regulation of cell proliferationGO:00082849.6CDK4, E2F3, HDAC1, MDM2
16positive regulation of transcription from RNA polymerase II promoterGO:00459448.9ARID4A, E2F1, E2F4, HDAC1, RB1, RBL1

Molecular functions related to Retinoblastoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1transcription factor bindingGO:000813410.0E2F4, HDAC1, RBL1
2transcription factor activity, sequence-specific DNA bindingGO:00037009.7E2F1, E2F3, HDAC1, RB1

Sources for Retinoblastoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet